Pfizer Inc. (PFE)
Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential
Pfizer is rated a buy due to its robust drug pipeline, focus on improving financials, and significant long-term growth potential despite near-term headwinds. PFE delivered strong results in H1, with 10% revenue growth, 30% higher adjusted income, and raised EPS guidance, with H2 expected to be even stronger. Risks include upcoming patent expirations, high dividend payout ratio, and political pressure on drug pricing, but the company is actively managing these challenges.
Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know
Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.
What's Behind The Slump In Pfizer Stock?
Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around $138 billion.
Pfizer: Don't Forget About Value During AI Frenzy
Pfizer is rated a Strong Buy, offering a nearly 7% forward dividend yield, which is highly likely safe. PFE's revenue has stabilized, management is delivering cost savings, and a recent drug pricing deal with the U.S. government reduces political uncertainty. The company's improving balance sheet, aggressive R&D, and undervalued stock price support long-term upside potential, despite sector headwinds.
Pfizer CEO says US pharma industry needs to collaborate with China
Pfizer Chief Executive Albert Bourla said on Tuesday that the U.S. pharmaceutical industry needs to collaborate with China's, where speedy processes have vaulted it to 30% of global drug development over the past decade.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
IP Group shares climb 9% on potential royalties from Pfizer's $7.3bn Metsera deal
Shares in IP Group PLC (LSE:IPO) rose 9% on Monday after investors welcomed the potential for future royalty income from Metsera, a biotech company that Pfizer has agreed to acquire for up to $7.3 billion. The agreement, announced in September, includes $4.9 billion in upfront cash and gives Pfizer control of Metsera's portfolio of next-generation obesity treatments.
IP Group in line for future royalties from Pfizer's drug deal
IP Group PLC (LSE:IPO) could see future royalty income from a new wave of obesity drugs being developed by Metsera, a biotech company that Pfizer Inc (NYSE:PFE, ETR:PFE) has agreed to buy for up to $7.3 billion. The deal, announced in late September, includes $4.9 billion in upfront cash and gives the US pharmaceutical giant control of a portfolio of next-generation obesity treatments.
4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer
Sometimes, things are going great for a stock with potentially more good news on the way. In other cases, things are going so badly for a stock that it almost has nowhere to go but up.
Here's Why Pfizer (PFE) Fell More Than Broader Market
In the latest trading session, Pfizer (PFE) closed at $25.24, marking a -1.71% move from the previous day.
Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
